R&D channel feed – Endpoints News

R&D channel feed

Positive PhIII can't salvage Merck's anacetrapib, now relegated to the scrap heap

8 years ago

Battered by mixed PhIII data, Trevena axes R&D staff and hunkers down around lead pain drug

8 years ago

Ardelyx steps up with a better round of PhIII data to compare with rivals at Ironwood, Synergy

8 years ago

Shooting for PhIII, Spero tees up a new lead antibiotic in-licensed cheap as it lines up $86M IPO

8 years ago

With just a little encouragement, biotech investors are ready to fall in love again

8 years ago

AbbVie jumps on the oncolytics bandwagon, embracing Turnstone in new collaboration

8 years ago

Eli Lilly concedes a PhIII flop for abemaciclib as breakout strategy flounders

8 years ago

Biotech scientist/entrepreneur Saurabh Saha makes an unusual return to the arms of a big — and excessively discreet — R&D group

8 years ago

'Going big': Merck launches frontline PhIII lung cancer study for Keytruda/Yervoy combo

8 years ago

In a setback, Bayer, J&J say their big PhIII secondary stroke trial for Xarelto failed

8 years ago

Acadia adopts a new PhIII game plan for 'breakthrough' med, dumps Alzheimer's PhII

8 years ago

Bluebird’s gene therapy shows promise in keeping lethal Lorenzo’s Oil disease in check

8 years ago

What failure? Catabasis shares soar after execs tout open-label data, PhIII plans

8 years ago

Following FDA debacle in ’09, Motif lines up a new shot at approval for antibiotic iclaprim

8 years ago

Amicus’ latest positive update on Pompe drug hints at accelerated approval pitch

8 years ago

Pushing the positive in p=0.05, RedHill says it’s ready for a pivotal IBD test

8 years ago

On a roll, Rigel flags a positive PhII for its lead, late-stage drug fostamatinib

8 years ago

Researchers go after the Holy Grail in flu research with the first big study for a universal jab

8 years ago

Top trend #4: We’re coming to a tipping point on cancer R&D, and it may not be pretty

8 years ago

Sam Kulkarni takes the helm at CRISPR Therapeutics as founding CEO steps down

8 years ago

Biohaven skunked by a placebo in PhII/III flop for ataxia drug, shares slide

8 years ago

Ablynx spikes as PhIII aTTP study comes through with promising data, setting up an FDA application

8 years ago

The hep C pipeline shrivels as Merck dumps two next-gen combos, boosting leader Gilead

8 years ago

Zogenix rockets up as PhIII study offers impressive data on Dravet syndrome, vaulting over a rival

8 years ago

First page Previous page 287 288 289290291 292 293 Next page Last page